Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Toxic, cytogenetic and antitumor evaluations of [6]-gingerol in non-clinical in vitro studies

2019; Elsevier BV; Volume: 115; Linguagem: Inglês

10.1016/j.biopha.2019.108873

ISSN

1950-6007

Autores

Rosália Maria Tôrres de Lima, Antonielly Campinho dos Reis, José Victor de Oliveira Santos, José Roberto de Oliveira Ferreira, Antônio Lima Braga, José Williams Gomes de Oliveira Filho, Ag‐Anne Pereira Melo de Menezes, Ana Maria Oliveira Ferreira da Mata, Marcus Vinícius Oliveira Barros de Alencar, Débora Caroline do Nascimento Rodrigues, Paulo Michel Pinheiro Ferreira, Teresinha de Jesus Aguiar dos Santos Andrade, Juan Carlos Ramos Gonçalves, Felipe Cavalcanti Carneiro da Silva, João Marcelo de Castro e Sousa, Ana Amélia de Carvalho Melo Cavalcante,

Tópico(s)

Drug Transport and Resistance Mechanisms

Resumo

Gingerol - [6]-gingerol ((S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-decanone; [6]-G) - is a phenolic compound with several pharmacological properties. Herein, the aim of the study was to evaluate the toxicogenic effects of [6]-G on Artemia salina nauplii, Allium cepa, HL-60 cell line and Sarcoma 180 (S-180) ascitic fluid cells.For toxic and genotoxic analysis, it was used [6]-G concentrations of 5, 10, 20 and 40 μg mL-1. For cytotoxic evaluation using the MTT test (3- [4,5-dimethyl-thiazol-2-yl] -2,5-diphenyl tetrazolium bromide), serial [6]-G dilutions (1.56-100 μg mL-1) were performed, and S-180, HL-60 and peripheral blood mononuclear cells (PBMC) were treated for 72 h. The IC50 of [6]-G were 1.14, 5.73 and 11.18 μg mL-1 for HL-60, S-180 and PBMC, respectively, indicating a possible selectivity against tumor cell lines. At higher concentrations (>10 μg mL-1), toxicity and genotoxicity were observed in the A. cepa test, especially at 40 μg mL-1. Mechanisms indicating apoptosis, such as toxicity, cytotoxicity and nuclear abnormalities (bridges, fragments, delays, loose chromosomes and micronuclei) suggest that [6]-G has potential for antitumor pharmaceutical formulations.

Referência(s)